Title: The heparin disaster : Chinese counterfeits and American failure : hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Tenth Congress, second session, April 29, 2008.
Authors: United States.
Publisher: U.S. G.P.O. : For sale by the Supt. of Docs., U.S. G.P.O.,
Year: 2008
Subjects: Heparin.; Pharmaceutical industry China.; Drug adulteration China.; Drug adulteration United States Prevention.; Heparin Toxicology United States.; Pharmaceutical policy United States
Contents: Contaminated heparin associated with adverse clinical events and activation of the contact system -- Plant in China under scrutiny -- China washes hands on heparin purity -- German firm recalls heparin with China link -- Three more European countries recall heparin -- Drug scare that exposed a world of hurt -- Heparin probe highlights challenges of regulating global drugs market -- Chemical sulfation of preparations of chondroitin 4-and 6-sulfate, and dermatan sulfate. Preparation of chondroitin sulfate E-like materials from chondroitin 4-sulfate -- Conformational changes and anticoagulant activity of chondroitin sulfate following its O-sulfonation -- Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events.